•
-
Business of Biology
Investor Roundtable Luncheon
Once a year we put the investors in a room by themselves. No startups. No pitches. No slides. Just the people actually moving capital across biotech and synthetic biology, talking honestly about what they're seeing: what's working, what might be overhyped, and where the real opportunities are right now. It's the conversation you can't have when founders are listening. It's invitation-only and space is limited
Featuring
Omri Amirav-Drory
NFX
General Partner
Scientist-founder VC: built Genome Compiler, now backs techbio.
Kid Parchariyanon
SeaX Ventures
Managing Partner
Physician-turned VC backing exponential deeptech and synbio.
David Welch
Synthesis Capital
CSO & Co-founder
Alt-protein scientist-investor, ex-Good Food Institute tech strategist.
Shelby Newsad
Compound
Partner
Scientist-turned-investor funding bold biotech bets.
Jessica Owens
Initiate Ventures
Managing Partner
Venture-studio builder, backing tech-bio moonshots.
•
-
Business of Biology
Investor Roundtable Luncheon
Once a year we put the investors in a room by themselves. No startups. No pitches. No slides. Just the people actually moving capital across biotech and synthetic biology, talking honestly about what they're seeing: what's working, what might be overhyped, and where the real opportunities are right now. It's the conversation you can't have when founders are listening. It's invitation-only and space is limited
Featuring
Omri Amirav-Drory
NFX
General Partner
Scientist-founder VC: built Genome Compiler, now backs techbio.
Kid Parchariyanon
SeaX Ventures
Managing Partner
Physician-turned VC backing exponential deeptech and synbio.
David Welch
Synthesis Capital
CSO & Co-founder
Alt-protein scientist-investor, ex-Good Food Institute tech strategist.
Shelby Newsad
Compound
Partner
Scientist-turned-investor funding bold biotech bets.
Jessica Owens
Initiate Ventures
Managing Partner
Venture-studio builder, backing tech-bio moonshots.
SynBioBeta is where the people building with biology meet the people funding, buying, and partnering with them. If you're raising capital, scouting the next wave of AIxBIO companies, or looking for your next technology partner - the people you need are here for three days.
The startups on stage this year are building programmable RNA medicines, virtual cell models, AI-designed enzymes, and proteins that replace sugar - alongside GSK, Sanofi, Novo Nordisk, Eli Lilly, J&J, Mars, Apple, Google, NVIDIA, Unilever, and P&G.
Watching where the partnerships form and which technologies the biggest players are actually evaluating is something you can't get from a report or a webinar. And our 1:1 Partnering App lets you book meetings before you arrive.
“SynBioBeta is a who’s who of AI and biology.
This is where the future is being built, so don't miss it”
“SynBioBeta is a who’s who of AI and biology.
This is where the future is being built, so don't miss it”
Eric Schmidt
Former CEO
"For every single fund at Boom Capital, one of our best companies has come directly from SynBioBeta. I met Mammoth Bio at SynBioBeta, and I met Nabla Bio at SynBioBeta."
Celestine Schnugg
Founder
"Nabla was accelerated into existence because of SynBioBeta. I met Seth Bannon from 50 Years, Cee Cee Schnugg from Boom Capital, and others from Y Combinator there, and those same people seeded Nabla. The vibe, leverage, and energy at SynBioBeta are unreal."
"Nabla was accelerated into existence because of SynBioBeta. I met Seth Bannon from 50 Years, Cee Cee Schnugg from Boom Capital, and others from Y Combinator there, and those same people seeded Nabla. The vibe, leverage, and energy at SynBioBeta are unreal."
Surge Biswas
Founder
"Our Series A came together because of a little bit of SynBioBeta magic. I’ve been attending for a decade and it’s been inspiring to watch the field evolve from a lot of hopes and dreams to real products and applications."
"Our Series A came together because of a little bit of SynBioBeta magic. I’ve been attending for a decade and it’s been inspiring to watch the field evolve from a lot of hopes and dreams to real products and applications."
Jacob Glanville
Founder & CEO
"I met Algen at SynBioBeta and later invested in the company. It’s exactly the kind of connection that makes the community so valuable."
"I met Algen at SynBioBeta and later invested in the company. It’s exactly the kind of connection that makes the community so valuable."
Bill Tai
Co-founder
"At SynBioBeta I met the team at Biomatter, an AI-driven enzyme design company. The environment made it easy to start a real conversation. That conversation turned into a collaboration to improve one of our enzymes. We're now exploring entirely new performance possibilities together."
"At SynBioBeta I met the team at Biomatter, an AI-driven enzyme design company. The environment made it easy to start a real conversation. That conversation turned into a collaboration to improve one of our enzymes. We're now exploring entirely new performance possibilities together."
Luis Cascao-Pereira
Head of Digital Biology
"Every time I attend SynBioBeta, I walk away with something transformative – a new investor, a fantastic hire, or an idea that changes how we work. It’s a community unlike any other."
"Every time I attend SynBioBeta, I walk away with something transformative – a new investor, a fantastic hire, or an idea that changes how we work. It’s a community unlike any other."
Ola Wlodek
CEO
